Newsroom
Sorted by: Latest
-
Doximity Partners with Aledade to Bring Clinical AI to Value-Based Care Settings
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced an integration with Aledade, a physician‑led, national leader in value‑based care. Through the agreement, Doximity will integrate components of its HIPAA-compliant Clinical AI Suite, including its ambient notetaking tool Scribe and clinical AI assistant Ask (formerly DoxGPT), into Aledade Assist™, Aledade’s EHR overlay that surfaces clinical insights at the p...
-
Omeros Corporation Reports First Quarter 2026 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million. Net income for the first quarter of...
-
Samenvatting: Boomi kondigt voornemen aan Lunar.dev over te nemen voor het leveren van beheerde agentconnectiviteit binnen de gehele onderneming
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Boomi, het data-activeringsbedrijf voor AI, heeft vandaag aangekondigd een intentieverklaring te hebben getekend voor de overname van Lunar.dev, een innovator op het gebied van AI- en MCP-gateways. De voorgestelde overname zal naar verwachting het Boomi Enterprise Platform en Boomi Connect verrijken met geavanceerde mogelijkheden om het gebruik van AI binnen bedrijfssystemen te beheren en op te schalen. Naarmate organisaties overstappen van AI-experimenten na...
-
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2026. “Adicet is approaching a key inflection point as we prepare to report Phase 1 data for prula-cel in mid-year 2026, including data from at least 20 LN and SLE patients with a minimum...
-
HeartBeam Reports First Quarter 2026 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2026 Results...
-
Doximity Announces Fourth Quarter and Fiscal Year 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 fourth quarter and fiscal year ended March 31, 2026. “We’re thrilled to announce that we reached a new engagement record of over 800,000 active prescribers using our workflow tools in Q4. Nearly half of those providers used our clinical AI last quarter, while our prompts per user nearly doubled from January to April alone,” said Jef...
-
Boomi annonce son intention d’acquérir Lunar.dev afin d’offrir une connectivité contrôlée des agents à l’échelle de l’entreprise
CONSHOHOCKEN, Pennsylvanie--(BUSINESS WIRE)--Boomi, spécialiste de l’activation des données pour l’IA, a annoncé aujourd’hui avoir signé une lettre d’intention en vue d’acquérir Lunar.dev, une entreprise innovante dans le domaine de l’IA et des passerelles MCP. Cette acquisition devrait enrichir la plateforme d’entreprise Boomi et Boomi Connect de capacités avancées permettant de gérer et de faire évoluer l’utilisation de l’IA à l’échelle des systèmes d’entreprise. À mesure que les organisation...
-
STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $5.2 million or $0.10 per diluted share, com...
-
Boomi plant die Akquisition von Lunar.dev zwecks verwalteter Konnektivität von Agenten innerhalb des Unternehmens
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Boomi, das Unternehmen für KI-Datenaktivierung, hat heute eine Absichtsvereinbarung über die Akquisition von Lunar.dev unterzeichnet, ein Innovator für KI und MCP Gateway. Durch die Akquisition würden die Boomi Enterprise Plattform und Boomi Connect mit fortschrittlichen Funktionen für die Verwaltung und Skalierung von KI in Unternehmenssystemen ausgestattet. Da Organisationen nun von KI-Experimenten zur Produktion übergehen, wird entscheidend, wie Agenten un...
-
Expedia Group to Webcast Explore 26 General Opening Session on May 19, 2026
SEATTLE--(BUSINESS WIRE)--Expedia Group (NASDAQ: EXPE) will webcast the general opening session of Explore 26, on May 19, 2026, at 2:00 p.m. PT. Explore 26 is Expedia Group’s annual partner event where the company will share new innovations focused on improving the complete travel experience for travelers and partners everywhere. The webcast will be available on the Investor Relations website; ir.expediagroup.com....